Lisa Polzien, Ph.D.

Director & Head of IP for Soluble and ACT Binders

Lisa Polzien joined Immatics in February 2022 and is responsible for all IP matters concerning soluble and ACT binders including patent portfolio management for soluble drug candidates and research methods, IP due diligence and IP negotiations with external partners.

After completion of studies in Biology with focus on molecular biology, biochemistry and microbiology, Lisa received a PhD at the Graduate School of Life Science at the University of Würzburg in the field of innovative cancer therapies. From 2011 to 2020, Lisa was working at the IP law firm Vossius & Partner where she was representing and consulting a spectrum of clients from global pharma/biotech companies as well as University research groups. She became a qualified European Patent Attorney in 2016. Lisa joined Sandoz (which was part of Novartis at that time) in 2020, where she was responsible for the worldwide IP strategy of various Sandoz’ products as well as for business development deals.

Lisa Polzien holds a Diploma in Biology from the University of Kiel, and did a Ph.D. (Dr. rer. nat.) in Biochemistry at the University of Würzburg. She passed the European Qualifying Examination (EQE) and became a qualified European Patent Attorney in 2016. Lisa completed the post-graduate studies "Law for patent attorneys” at the University of Hagen in 2018. She was listed as a representative before the Unified Patent Court (UPC) in 2023.